A new study led by researchers at the Hospital for Special Surgery (HSS) suggests that currently available therapies may help ...

The CHMP recommends conditional marketing authorization for Duvyzat to treat Duchenne muscular dystrophy in patients aged 6 ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the latest treatment advancements for Duchenne muscular dystrophy.

John Brandsema, MD, a pediatric neurologist at Children’s Hospital of Philadelphia, speaks with Healio about the importance of early diagnosis of muscular dystrophy.

On that occasion treatment with Alexion ... drug to be used if needed. There are fears that following disappointing results at the lower dose level in IIGNITE DMD, a safety issue at higher ...

Multidisciplinary coordination across prescribing teams, nursing, laboratory medicine, finance, and infusion centers is ...

Eteplirsen may delay cardiac deterioration in DMD patients by reducing the risk of reaching LVEF decline thresholds. None of the eteplirsen-treated patients reached an LVEF below 50%, compared to ...

This process is worsened by increased levels of histone deacetylases (HDAC), a class of proteins. There is no cure for DMD and treatment is centred on corticosteroid therapy, prevention of ...

Upon approval, vamorolone would be the first and only treatment option indicated for patients diagnosed with Duchenne muscular dystrophy in Canada The Canadian regulatory submission of vamorolone ...

WALTHAM, Mass. - The European Commission (EC) has granted orphan drug designation to Dyne Therapeutics, Inc.’s (NASDAQ:DYNE) DYNE-251, a potential treatment for Duchenne muscular dystrophy (DMD). This ...